{
    "root": "2fbaa94f-8f85-69f0-e063-6294a90a361b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Celecoxib",
    "value": "20250307",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_41423"
        }
    ],
    "indications": {
        "text": "celecoxib indicated",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) \u2022 oa : 200 mg daily 100 mg twice daily . ( 2.2 , 14.1 ) \u2022 rheumatoid arthritis : 100 mg 200 mg twice daily . ( 2.3 , 14.2 ) \u2022 jra : 50 mg twice daily patients 10 kg 25 kg . 100 mg twice daily patients 25 kg . ( 2.4 , 14.3 ) \u2022 : 200 mg daily single dose 100 mg twice daily . effect observed 6 weeks , trial 400 mg ( single divided doses ) may benefit . ( 2.5 , 14.4 ) \u2022 ap pd : 400 mg initially , followed 200 mg dose needed first day . subsequent days , 200 mg twice daily needed . ( 2.6 , 14.5 ) hepatic impairment : reduce daily dose 50 % patients moderate hepatic impairment ( child-pugh class b ) . ( 2.7 , 8.6 , 12.3 ) poor metabolizers cyp2c9 substrates : consider dose reduction 50 % ( alternative management jra ) patients known suspected cyp2c9 poor metabolizers . ( 2.7 , 8.8 , 12.3 ) .",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "celecoxib capsules 50 mg opaque white/opaque white hard gelatin capsules size \u201c 5 \u201d imprinting \u201c 134 \u201d body red ink \u201c \u201d cap red ink filled white off-white colored granular powder . ndc 62332-140-30 bottle 30 capsules ndc 62332-140-60 bottle 60 capsules ndc 62332-140-91 bottle 1000 capsules ndc 62332-140-08 carton 80 ( 10 x 8 ) unit-dose capsules ndc 62332-140-10 carton 100 ( 10 x 10 ) unit-dose capsules celecoxib capsules 100 mg opaque white/opaque white hard gelatin capsules size \u201c 3 \u201d imprinting \u201c 135 \u201d body blue ink \u201c \u201d cap blue ink filled white off-white colored granular powder . ndc 62332-141-30 bottle 30 capsules ndc 62332-141-60 bottle 60 capsules ndc 62332-141-31 bottle 100 capsules ndc 62332-141-71 bottle 500 capsules ndc 62332-141-91 bottle 1000 capsules ndc 62332-141-08 carton 80 ( 10 x 8 ) unit-dose capsules ndc 62332-141-10 carton 100 ( 10 x 10 ) unit-dose capsules celecoxib capsules 200 mg opaque white/opaque white hard gelatin capsules size \u201c 1 \u201d imprinting \u201c 136 \u201d body golden yellow ink \u201c \u201d cap golden yellow ink filled white off-white colored granular powder . ndc 62332-142-30 bottle 30 capsules ndc 62332-142-60 bottle 60 capsules ndc 62332-142-31 bottle 100 capsules ndc 62332-142-71 bottle 500 capsules ndc 62332-142-91 bottle 1000 capsules ndc 62332-142-08 carton 80 ( 10 x 8 ) unit-dose capsules ndc 62332-142-10 carton 100 ( 10 x 10 ) unit-dose capsules celecoxib capsules 400 mg opaque white/opaque white hard gelatin capsules size \u201c 00 \u201d imprinting \u201c 137 \u201d body green ink \u201c \u201d cap green ink filled white off-white colored granular powder . ndc 62332-143-30 bottle 30 capsules ndc 62332-143-60 bottle 60 capsules ndc 62332-143-71 bottle 500 capsules ndc 62332-143-10 carton 100 ( 10 x 10 ) unit-dose capsules ndc 62332-143-14 carton 126 ( 9 x 14 ) unit-dose capsules storage : store 20\u00b0-25\u00b0c ( 68\u00b0-77\u00b0f ) excursions permitted 15\u00b0-30\u00b0c ( 59\u00b0- 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "celecoxib contraindicated following patients : \u00b7 known hypersensitivity ( e.g . , anaphylactic serious skin ) celecoxib , components product [ ( 5.7 , 5.9 ) ] . \u00b7 history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids , reported patients [ ( 5.7 , 5.8 ) ] . \u00b7 setting cabg surgery [ ( 5.1 ) ] . \u00b7 patients demonstrated allergic-type sulfonamides [ ( 5.7 ) ] .",
    "indications_original": "Celecoxib is indicated",
    "contraindications_original": "\u2022\u00a0 Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. (2.1) \u2022\u00a0 OA: 200 mg once daily or 100 mg twice daily. (2.2, 14.1) \u2022\u00a0 RA: 100 mg\u00a0to 200 mg twice daily. (2.3, 14.2) \u2022\u00a0 JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg. (2.4, 14.3) \u2022\u00a0 AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit. (2.5, 14.4) \u2022\u00a0 AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed. (2.6, 14.5) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). (2.7, 8.6, 12.3) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers. (2.7, 8.8, 12.3).",
    "warningsAndPrecautions_original": "Celecoxib capsules 50 mg are opaque white/opaque white hard gelatin capsules size \u201c5\u201d having imprinting \u201c134\u201d on body with red ink and \u201cA\u201d on cap with red ink filled with white to off-white colored granular powder.\u00a0\n                  \n                  NDC 62332-140-30\u00a0\u00a0\u00a0 bottle of 30 capsules\u00a0\n                  NDC 62332-140-60\u00a0\u00a0\u00a0 bottle of 60 capsules\u00a0\n                  NDC 62332-140-91\u00a0\u00a0\u00a0 bottle of 1000 capsules\u00a0\n                  NDC 62332-140-08 \u00a0\u00a0 carton of 80 (10 x 8) unit-dose capsules\u00a0\n                  NDC 62332-140-10 \u00a0\u00a0 carton of 100 (10 x 10) unit-dose capsules\n                  \n                  Celecoxib capsules 100 mg are opaque white/opaque white hard gelatin capsules size \u201c3\u201d having imprinting \u201c135\u201d on body with blue ink and \u201cA\u201d on cap with blue ink filled with white to off-white colored granular powder.\n                  \n                  NDC 62332-141-30\u00a0\u00a0\u00a0 bottle of 30 capsules\u00a0\n                  NDC 62332-141-60\u00a0\u00a0\u00a0 bottle of 60 capsules\u00a0\n                  NDC 62332-141-31\u00a0\u00a0\u00a0 bottle of 100 capsules\u00a0\n                  NDC 62332-141-71\u00a0\u00a0\u00a0 bottle of 500 capsules\u00a0\n                  NDC 62332-141-91\u00a0\u00a0\u00a0 bottle of 1000 capsules\u00a0\n                  NDC 62332-141-08 \u00a0\u00a0 carton of 80 (10 x 8) unit-dose capsules\u00a0\n                  NDC 62332-141-10 \u00a0\u00a0 carton of 100 (10 x 10) unit-dose capsules\n                  \n                  Celecoxib capsules 200 mg are opaque white/opaque white hard gelatin capsules size \u201c1\u201d having imprinting \u201c136\u201d on body with golden yellow ink and \u201cA\u201d on cap with golden yellow ink filled with white to off-white colored granular powder.\n                  \n                  NDC 62332-142-30\u00a0\u00a0\u00a0 bottle of 30 capsules\u00a0\n                  NDC 62332-142-60\u00a0\u00a0\u00a0 bottle of 60 capsules\u00a0\n                  NDC 62332-142-31\u00a0\u00a0\u00a0 bottle of 100 capsules\u00a0\n                  NDC 62332-142-71\u00a0\u00a0\u00a0 bottle of 500 capsules\u00a0\n                  NDC 62332-142-91\u00a0\u00a0\u00a0 bottle of 1000 capsules\u00a0\n                  NDC 62332-142-08 \u00a0\u00a0 carton of 80 (10 x 8) unit-dose capsules\u00a0\n                  NDC 62332-142-10 \u00a0\u00a0 carton of 100 (10 x 10) unit-dose capsules\u00a0\n                  \u00a0\u00a0\n                  Celecoxib capsules 400 mg are opaque white/opaque white hard gelatin capsules size \u201c00\u201d having imprinting \u201c137\u201d on body with green ink and \u201cA\u201d on cap with green ink filled with white to off-white colored granular powder.\n                  \n                  NDC 62332-143-30\u00a0\u00a0\u00a0 bottle of 30 capsules\u00a0\n                  NDC 62332-143-60\u00a0\u00a0\u00a0 bottle of 60 capsules\u00a0\n                  NDC 62332-143-71\u00a0\u00a0\u00a0 bottle of 500 capsules\u00a0\n                  NDC 62332-143-10 \u00a0\u00a0 carton of 100 (10 x 10) unit-dose capsules\u00a0\n                  NDC 62332-143-14 \u00a0\u00a0 carton of 126 (9 x 14) unit-dose capsules\n \n  \n                        \u00a0\n                     \u00a0\n\n \n                  \n                     \n                        Storage\n                     \n                     :Store at 20\u00b0-25\u00b0C (68\u00b0-77\u00b0F) excursions permitted to 15\u00b0-30\u00b0C (59\u00b0- 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Celecoxib is contraindicated in the following patients:\n                  \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions)to\u00a0celecoxib, any components of the drug product [\n \n  see Warnings and Precautions (5.7,\u00a0\u00a0\u00a05.9)].\n\n \n                  \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other\u00a0\u00a0\u00a0NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 reported in such patients [\n \n  see Warnings and Precautions (5.7, 5.8)].\n\n \n                  \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In the setting of CABG surgery [\n \n  see Warnings and\u00a0\u00a0Precautions (5.1)].\n\n \n                  \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In patients who have demonstrated allergic-type reactions to sulfonamides [\n \n  see \u00a0Warnings and Precautions (5.7)].",
    "drug": [
        {
            "name": "Celecoxib",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_41423"
        }
    ]
}